WO2020101596A3 - A capsule composition comprising sunitinib - Google Patents

A capsule composition comprising sunitinib Download PDF

Info

Publication number
WO2020101596A3
WO2020101596A3 PCT/TR2019/050579 TR2019050579W WO2020101596A3 WO 2020101596 A3 WO2020101596 A3 WO 2020101596A3 TR 2019050579 W TR2019050579 W TR 2019050579W WO 2020101596 A3 WO2020101596 A3 WO 2020101596A3
Authority
WO
WIPO (PCT)
Prior art keywords
sunitinib
capsule composition
capsule
composition
present
Prior art date
Application number
PCT/TR2019/050579
Other languages
French (fr)
Other versions
WO2020101596A2 (en
Inventor
Ali Turkyilmaz
Yuksel TOPALOGLU
Ali Ihsan SECKIN
Irem Yenice
Original Assignee
Arven Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arven Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Arven Ilac Sanayi Ve Ticaret Anonim Sirketi
Publication of WO2020101596A2 publication Critical patent/WO2020101596A2/en
Publication of WO2020101596A3 publication Critical patent/WO2020101596A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Abstract

The present invention relates to a capsule comprising sunitinib and at least one binder. Further, the present invention provides a method for the preparation of the said composition.
PCT/TR2019/050579 2018-08-10 2019-07-16 A capsule composition comprising sunitinib WO2020101596A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR201811687 2018-08-10
TR2018/11687 2018-08-10

Publications (2)

Publication Number Publication Date
WO2020101596A2 WO2020101596A2 (en) 2020-05-22
WO2020101596A3 true WO2020101596A3 (en) 2020-07-09

Family

ID=70730567

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2019/050579 WO2020101596A2 (en) 2018-08-10 2019-07-16 A capsule composition comprising sunitinib

Country Status (1)

Country Link
WO (1) WO2020101596A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113440495B (en) * 2021-07-14 2022-07-12 北京鑫开元医药科技有限公司 Sunitinib malate capsule and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013160916A1 (en) * 2012-04-25 2013-10-31 Hetero Research Foundation Sunitinib malate solid dispersion
CN104069076A (en) * 2013-03-29 2014-10-01 浙江九洲药业股份有限公司 Unshaped composition of sunitinib and PVP (Polyvinyl Pyrrolidone)
CN105434399A (en) * 2015-12-24 2016-03-30 湖南尔康制药股份有限公司 Renal cell carcinoma treatment medicine sunitinib-PLGA/Fe3O4 composite microsphere and preparation method thereof
WO2017181187A1 (en) * 2016-04-15 2017-10-19 Exelixis, Inc. Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
EP3539536A1 (en) * 2018-03-15 2019-09-18 MH10 Spolka z ograniczona odpowiedzialnoscia A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013160916A1 (en) * 2012-04-25 2013-10-31 Hetero Research Foundation Sunitinib malate solid dispersion
CN104069076A (en) * 2013-03-29 2014-10-01 浙江九洲药业股份有限公司 Unshaped composition of sunitinib and PVP (Polyvinyl Pyrrolidone)
CN105434399A (en) * 2015-12-24 2016-03-30 湖南尔康制药股份有限公司 Renal cell carcinoma treatment medicine sunitinib-PLGA/Fe3O4 composite microsphere and preparation method thereof
WO2017181187A1 (en) * 2016-04-15 2017-10-19 Exelixis, Inc. Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
EP3539536A1 (en) * 2018-03-15 2019-09-18 MH10 Spolka z ograniczona odpowiedzialnoscia A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i

Also Published As

Publication number Publication date
WO2020101596A2 (en) 2020-05-22

Similar Documents

Publication Publication Date Title
EP3875458A4 (en) Diphenyl-like compound, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and uses thereof
WO2018109174A3 (en) Il-11 antibodies
WO2019020602A3 (en) Phosphor and a composition
WO2020039321A3 (en) Anti-gdf15 antibodies, compositions and methods of use
EP4248965A3 (en) Compounds, compositions and methods
WO2018109170A3 (en) Il-11ra antibodies
AU2018258581A8 (en) RAF-degrading conjugate compounds
EP3923935A4 (en) Compounds, compositions and methods
MX2020014013A (en) Sweetener powder composition and preparation method therefor.
EP3924341A4 (en) Compounds, compositions and methods
MX2022010755A (en) Kinase inhibitors and uses thereof.
MX2020002123A (en) Ribociclib salts and solid state forms thereof.
WO2018101663A3 (en) Composition for biotissue clearing and biotissue clearing method using same
WO2018127612A3 (en) Compositions comprising lespedeza plant extract
PH12020550125A1 (en) Crystalline forms of 3-substituted 1,2,4-oxadiazole
EP3873911A4 (en) Compounds, compositions, and methods for modulating cdk9 activity
WO2020131586A3 (en) Methods for identifying neoantigens
WO2019027173A3 (en) Novel psicose-6-phosphate phosphatase, composition for producing psicose including said enzyme, method for producing psicose using said enzyme
MX2021003180A (en) Methods and kits for preparing pathogen-inactivated whole blood.
CR20220112A (en) Compositions comprising tigolaner for controlling parasites
PH12021550413A1 (en) Vitamin d pediatric dosage forms, methods of making and using
EP3670511A4 (en) Tetrahydroprotoberberine compound, preparation method therefor and uses thereof, and pharmaceutical composition
EP3953348A4 (en) Compounds, compositions and methods
EP3757137A4 (en) P-boronophenylalanine derivative and composition containing same, and kit for producing said derivative and composition
AU2018279184A1 (en) Anti-TrkB antibodies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19884360

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19884360

Country of ref document: EP

Kind code of ref document: A2